What do oncologists need to know about biosimilar products?

por Leung, Linda K. S., Mok, Kevin, Liu, Calvin, Chan, Stephen L.
Publicado 2016

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Tan, S. C., Jen, Jason, Lee, Mary Y. K., Aguiar-Ibáñez, Raquel, Wang, Jingshu
Publicado 2020

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Chan, Catherine P. K., Chang, Andrea, Zhou, Zheng-Yi, Xie, Jipan, Gibbs, Meaghan
Publicado 2020

Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas

por Loong, Herbert Ho-fung, Wong, Carlos King Ho, Wei, Yihui, Kwan, Sampson Sui Chun, Zhang, Yingjun, Tse, Teresa, Lau, Yat-Ming, Leung, Linda K S, Tang, Gordon C H
Publicado 2020

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, Tan, Seng Chuen
Publicado 2019

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data

por Li, Leung, Mo, Frankie KF, Chan, Stephen L, Hui, Edwin P, Tang, Nelson SL, Koh, Jane, Leung, Linda KS, Poon, Annette NY, Hui, Joyce, Chu, Cheuk M, Lee, Kit F, Ma, Brigette BY, Lai, Paul BS, Chan, Anthony TC, Yu, Simon CH, Yeo, Winnie
Publicado 2017